Eagle Pharmaceuticals Inc (EGRX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eagle Pharmaceuticals, Inc. is on the clock to file its overdue quarterly report after receiving a delinquency notice from Nasdaq for not complying with listing rules. They’ve been granted a 180-day extension until May 13, 2024, to submit their financials and avoid delisting. The company’s future on the stock market hangs in the balance as they work to meet the deadline and maintain their listing status.
For further insights into EGRX stock, check out TipRanks’ Stock Analysis page.